🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections per year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This medication, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Worldwide Availability

Based on findings released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves two antibiotics. The trial involved over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced optimism. The availability of a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.